Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BIO-106 |
| Synonyms | |
| Therapy Description |
BIO-106 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to an undisclosed tubulin inhibitor, potentially resulting in cell cycle arrest, apoptosis, and decreased proliferation of tumor cells expressing TROP2 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BIO-106 | BIO 106|BIO106 | TROP2 Antibody 18 | BIO-106 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to an undisclosed tubulin inhibitor, potentially resulting in cell cycle arrest, apoptosis, and decreased proliferation of tumor cells expressing TROP2 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05320588 | Phase Ib/II | BIO-106 BIO-106 + Pembrolizumab | A Phase 1/2 Study in Patients With Advanced Cancers | Recruiting | USA | 0 |